Master Services Agreement

Exhibit 10.10

**CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Master Services Agreement

This Master Services Agreement (“Agreement”) is made on the 25^th day of June 2004, by and between:

and

WHEREAS

Page 1 of 13

NOW, FOR GOOD AND VALUABLE CONSIDERATION (THE SUFFICIENCY OF WHICH IS ACKNOWLEDGED BY BOTH PARTIES), IT IS HEREBY AGREED AS FOLLOWS:

Page 2 of 13

Page 3 of 13

Page 4 of 13

Ownership of the Know-How, Intellectual Property Rights relating to the Know-How and all other Intellectual Property Rights resides exclusively in Argenes and/or its Affiliates. MediciNova agrees to assign and hereby assigns to Argenes and will require all of its Suppliers to agree to assign to Argenes all rights MediciNova or its Affiliates, directors, officers, employees, representatives or Suppliers may have in any Know-How and Intellectual Property Rights and agrees to assist Argenes, at Argenes’ expense, in obtaining or extending protection and agrees to do any act or execute any document as may be required in order to enable ownership of such rights to be vested in Argenes. MediciNova represents that it has and will continue to have agreements with its Affiliates, directors, officers, employees, agents, representatives and Suppliers to effectuate the terms of this Section and that it will enforce such agreements to provide Argenes with the benefit of this Section. Notwithstanding the foregoing, Argenes acknowledges that MediciNova possesses certain inventions, processes, know-how, trade secrets, improvements, and other intellectual properties and other assets including, but not limited to, analytical methods, procedures and techniques, procedure manuals, personnel data, financial information, computer technical expertise and software, which have been independently developed by MediciNova and which relate to MediciNova’s business or operations (collectively, “MediciNova Property”). Argenes and MediciNova agree that any MediciNova Property or improvements thereto which are used, improved, modified, or developed by MediciNova under or during the term of this Agreement are the sole and exclusive property of MediciNova, provided that MediciNova will not, without Argenes’ prior written consent, integrate MediciNova Property into any process or procedure such that future practice of the process or procedure would require a license to use such MediciNova Property.

Page 5 of 13

Page 6 of 13

Upon at least twenty days’ advance notice from Argenes, MediciNova will make said records available to representatives or agents of Argenes in MediciNova’s offices for the purposes of auditing said records to verify MediciNova’s or its Suppliers’ compliance with the terms of this Agreement.

Page 7 of 13

In the event information confidential to a third party is contained on any records subject to audit by Argenes, such records may be reviewed by an independent auditor appointed by Argenes. Such independent auditor will sign in advance of inspection a confidential disclosure agreement suitable in form to Argenes, MediciNova, and the appointed auditor.

If the performance of this Agreement or any obligation under it is prevented, restricted or interfered with by reason of circumstances beyond the reasonable control of that Party obliged to perform it (including, without limitation, flood, fire, storm, strike, lockout, sabotage, terrorist act, civil commotion and government intervention), the Party so affected will (upon giving prompt notice thereof to the other Party) be excused from performance to the extent only of the prevention, restriction or interference, provided always that the Party so affected will use its reasonable endeavours to avoid or remove the causes of non-performance and will continue performance as expeditiously as possible as soon as such causes have been removed. In case the delay caused by Force Majeure exceeds one month the Parties will meet to discuss the situation, and the Party suffering from the non-performance of the other party will have the right to terminate this Agreement.

Page 8 of 13

Any notice or other document to be given under this Agreement will be in writing and will be deemed to have been duly given if sent by first class post, registered post, internationally recognized overnight courier, or facsimile (provided in the latter case that a confirmatory copy is sent by post on the same day) to a Party at the address or facsimile

Page 9 of 13

number set out below or such other address as a Party may from time to time designate by written notice to the other Parties:

Page 10 of 13

IN WITNESS WHEREOF this Agreement has been executed by duly authorized officers of the Parties.

Page 11 of 13

Master Service Agreement between Argenes Inc. (ARGENES)

and MediciNova, Inc. (MEDICINOVA)

Addendum 1

To further the clinical utility of an [**] as a potential treatment for [**], ARGENES wishes to conduct Phase I testing in [**].

MEDICINOVA will provide the following services to ARGENES in support of a Phase I trial of its anti-APO-1/Fas mA:

CRO audit and selection

CRO contract negotiation

Investigator’s Brochure review

CMC review

Review analytical methods/validation

Protocol & Informed Consent design & review

Maintain a regulatory document file

Coordinate CTM delivery

Clinical trial monitoring

Coordinate pharmacokinetics sample delivery

Periodic safety review

Review/edit final study report

These services will be performed by, or under the direct supervision of, Dr. Kenneth W. Locke, Sr. VP, Portfolio Management of MEDICINOVA. Completion of the above services will be completed no later than 4 weeks after the receipt of the final study report by MEDICINOVA for review/editing.

In consideration for these services, ARGENES agrees to pay MEDICINOVA monthly within 30 days of the receipt of the invoice from MEDICINOVA. The hourly rate of MEDICINOVA fee is USD [**]. It is expected that the aggregated required hours for the service is less than [**] hours per year.

The above consideration does not include CRO costs for conduct of the study, product-associated costs, analysis of plasma/serum samples or interpretation of pharmacokinetic study results, incidental costs (e.g., any shipping charges or tariffs/duties) or travel costs incurred by MEDICINOVA in the course of conducting the Phase I study. All such charges are the responsibility of ARGENES and are payable in U.S. dollars within 30 days of invoice by MEDICINOVA.

Page 12 of 13

Page 13 of 13